Newly Diagnosed H3-mutated Glioma — A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
Citation(s)
A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas - (INTERCEPT-H3)